There will be an average drop of almost 20% in the price of 288 medicines from December 1, the Federal Office of Public Health says. Savings of around CHF100 million ($100 million) are expected.
The move comes at a time of debate over the high costs of medicines in Switzerland.
The price reduction, which averages 18.8%, will for example affect Dafalgan (paracetamol), ASS Cardio (aspirin) and children’s oral drops Becetamol. Some medicines will even see a drop in price of up to 30%, with a 50% reductionExternal link for the diuretic Aldactone, a medicine used for high blood pressure.
In a statement on FridayExternal link, the health office said 255 medicines would see no price change because they were “economically sustainable” in Switzerland compared with abroad and with other medicines.
It also took a look at generic medicines, co-marketing medicinesExternal link (same product, different brands) and biosimilars (almost identical copy of original product) and found price reductions could be made in 134 out of 237 cases.
This is the second timeExternal link that the health office has cut the price of medicines, the first time coming at the end of 2017. This has allowed for definite savings in this case of CHF225 million, over 350 medicines, the health office said. This was more than the expected CHF190 million.
Debate
There has been much debate in Switzerland about the cost of medicines. In September the government announced its intention to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
In spring it was revealed that generic drugs cost twice as much in Switzerland as in other parts of Europe. Patented drugs were 9% more expensive, a study found.
Several groups, including the price watchdog, consumer advocates and the umbrella organisation of health insurers, have been calling for years for prices to be reduced.
More
More
What’s being done to bring down high drug costs?
This content was published on
We unravel part of the tangled web of players and factors that influence prices of drugs in the US and Switzerland.
Swiss government adopts three-pronged approach to end violence against women
This content was published on
Over the next few years, the federal government intends to take action against gender-based violence in three main areas.
Uri voters clear path for hotel and marina complex in central Switzerland
This content was published on
Voters in canton Uri in central Switzerland have rejected a Green Party initiative aimed at regulating the development of the lakeside site in Isleten.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Costs of generic drugs and outpatient services targeted
This content was published on
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
Swiss campaign to make lifesaving drugs affordable
This content was published on
Swiss authorities must act to make lifesaving drugs more affordable by introducing compulsory licensing, says NGO Public Eye.
Meet the man trying to make Switzerland less expensive
This content was published on
Switzerland has an official price watchdog – someone who fights unfair prices that hurt consumers. Where does he see potential for savings?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.